Pentoxifylline reduces venular leukocyte adherence ('reflow paradox') but not microvascular 'no reflow' in hepatic ischemia/reperfusion

Journal of Surgical Research

Volumn 71, Issue 1, 1997, Pages 1-6

  Müller, Josef M ^a   Vollmar, Brigitte ^a   Menger, Michael D ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PENTOXIFYLLINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE ADHERENCE INHIBITION; LIVER ISCHEMIA; LIVER PERFUSION; LIVER SINUSOID; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; VENULE;

EID: 0031571179     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1997.5132     Document Type: Article

References (41)

1. Menger M. D., Vollmar B., Glasz J., Post S., Messmer K. Microcirculatory manifestations of hepatic ischemia/reperfusion injury. Prog. Appl. Microcirc. 19:1993;106.
2. Koo A., Komatsu H., Tao G., Inoue M., Guth P. H., Kaplowitz N. Contribution of no-reflow phenomenon to hepatic injury after ischemia-reperfusion: Evidence for a role for superoxide anion. Hepatology. 15:1992;507.
3. Menger M. D., Steiner D., Messmer K. Microvascular ischemia-reperfusion injury in striated muscle: Significance of "no-reflow" Am. J. Physiol. 263:1992;H1892.
4. Vollmar B., Glasz J., Post S., Leiderer R., Menger M. D. Hepatic microcirculatory perfusion failure is a determinant for liver dysfunction in warm ischemia-reperfusion. Am. J. Pathol. 145:1994;1421.
5. Granger D. N., Benoit J. N., Suzuki M., Grisham M. B. Leukocyte adherence to venular endothelium during ischemia-reperfusion. Am. J. Physiol. 257:1989;G683.
6. Menger M. D., Pelikan S., Steiner D., Messmer K. Microvascular ischemia-reperfusion injury in striated muscle: Significance of "reflow-paradox" Am. J. Physiol. 263:1992;H1901.
7. Vollmar B., Menger M. D., Glasz J., Leiderer R., Messmer K. Impact of leukocyte-endothelial cell interaction in hepatic ischemia/reperfusion injury. Am. J. Physiol. 267:1994;G786.
8. Menger M. D., Sack F. U., Barker J. H., Feifel G., Messmer K. Quantitative analysis of microcirculatory disorders after prolonged ischemia in skeletal muscle: Therapeutic effects of prophylactic isovolemic hemodilution. Res. Exp. Med. 188:1998;151.
9. Menger M. D., Steiner D., Pelikan S., Messmer K. Buflomedil hydrochloride attenuates tourniquet-induced microvascular reperfusion injury in striated muscle. Int. J. Microcirc. Clin. Exp. 14:1994;296.
10. Nolte D., Hecht R., Schmid P., Botzlar A., Menger M. D., Neumueller C., Sinowatz F., Vestweber D., Messmer K. Role of Mac-1 and ICAM-1 in ischemia-reperfusion injury in a microcirculation model of Balb/C-mice. Am. J. Physiol. 267:1994;H1320.
11. Vollmar B., Glasz J., Menger M. D., Messmer K. Leukocytes contribute to hepatic ischemia/reperfusion injury via intercellular adhesion molecule-1-mediated venular adherence. Surgery. 117:1995;195.
12. Kubes P., Ibbotson G., Russell J., Wallace J. L., Granger D. N. Role of platelet-activating factor in ischemia/reperfusion-induced leukocyte adherence. Am. J. Physiol. 259:1990;G300.
13. Lehr H. A., Guhlmann A., Nolte D., Keppler D., Messmer K. Leukotrienes as mediators in ischemia-reperfusion injury in a microcirculation model in the hamster. J. Clin. Invest. 87:1991;2036.
14. Ward A., Clissold S. P. Pentoxifylline: A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs. 34:1987;50.
15. Mollitt D. L., Poulos N. D. The role of pentoxifylline in endotoxin-induced alterations of red blood cell deformability and whole blood viscosity in the neonate. J. Pediatr. Surg. 26:1991;572.
16. Badger A. M., Olivera D. L., Esser K. M. Beneficial effects of the phosphodiesterase inhibitors BRL 61063, pentoxifylline, and rolipram in a murine model of endotoxin shock. Circ. Shock. 44:1994;188.
17. Barton M. H., Moore J. N. Pentoxifylline inhibits mediator synthesis in an equine in vitro whole blood model of endotoxemia. Circ. Shock. 44:1994;216.
18. Nakagawa K., Millerm F. N., Knott A. W., Edwards M. J. Pentoxifylline inhibits FMLP-induced macromolecular leakage. Am. J. Physiol. 269:1995;H239.
19. Lindgärde F., Jelnes R., Björkman H., Adielsson G., Kjellström T., Palmquist I., Stavenow L. Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Circulation. 80:1989;1549.
20. Peng X.-X., Currin R. T., Thurman R. G., Lemasters J. J. Protection by pentoxifylline against normothermic liver ischemia/reperfusion in rats. Transplantation. 59:1995;1537.
21. Barroso-Aranda J., Schmid-Schönbein G. W. Pentoxifylline pretreatment decreases the pool of circulating activated neutrophils,in-vivo. Biorheology. 27:1990;401.
22. Hoffmann H., Hatherill J. R., Crowley J., Harada H., Yonemaru M., Zheng H., Ishizaka A., Raffin T. A. Early post-treatment with pentoxifylline or dibutyryl cAMP attenuatesEscherichia coli. Am. Rev. Respir. Dis. 143:1991;289.
23. Tighe D., Moss R., Hynd J., Boghossian S., Al-Saady N., Heath M. F. Pretreatment with pentoxifylline improves the hemodynamic and histologic changes and decreases neutrophil adhesiveness in a pig fecal peritonitis model. Crit. Care Med. 8:1990;184.
24. Needham D., Armstrong M., Hatchell D. L., Nunn R. S. Rapid deformation of "passive" polymorphonuclear leukocytes: The effects of pentoxifylline. J. Cell. Physiol. 140:1989;549.
25. Wong P. M., Schmid-Schönbein G. W. Attenuation of spontaneous pseudopod formation in human neutrophils by pentoxifylline. Cell Biophys. 18:1991;203.
26. Currie M. S., Rao K. M., Padmanabhan J., Jones A., Crawford J., Cohen H. J. Stimulus-specific effects of pentoxifylline on neutrophil CR3 expression, degranulation and superoxide production. J. Leukoc. Biol. 47:1990;244.
27. Zabel P., Wolter D. T., Schönharting M. M., Schade U. F. Oxpentifylline in endotoxemia. Lancet. 2:1989;1474.
28. Kovach N. L., Lindgren C. G., Fefer A., Thompson J. A., Yednock T., Harlan J. M. Pentoxifylline inhibits integrin-mediated adherence of interleukin-2-activated human peripheral blood lymphocytes to human umbilical vein endothelial cells, matrix components, and cultured tumor cells. Blood. 84:1994;2234.
29. Lehr H. A., Krombach F., Münzing S., Bodlaj R., Glaubitt S. I., Seiffge D., Hübner C., von Andrian U. H., Messmer K. In vitroin vivo. Am. J. Pathol. 146:1995;218.
30. Mángy Y., Farkas G., Ocsovszky I., Nagy Z. Inhibition of tumor necrosis factor production and ICAM-1 expression by pentoxifylline: Beneficial effects in sepsis syndrome. Res. Exp. Med. 195:1995;297.
31. Wanner G. A., Ertel W., Müller P., Höfer Y., Leiderer R., Menger M. D., Messmer K. Liver ischemia and reperfusion induces a systemic inflammatory response through Kupffer cell activation. Shock. 5:1996;34.
32. Granger D. N., Kubes P. The microcirculation and inflammation: Modulation of leukocyte-endothelial cell adhesion. J. Leukoc. Biol. 55:1994;662.
33. Flynn W. J., Cryer H. G., Garrison R. N. Pentoxifylline but not saralasin restores hepatic blood flow after resuscitation from hemorrhagic shock. J. Surg. Res. 50:1991;616.
34. Flynn W. J., Cryer H. G., Garrison R. N. Pentoxifylline restores intestinal microvascular blood flow during resuscitated hemorrhagic shock. Surgery. 110:1991;350.
35. Slaaf D. W., Reneman R. S., Wiederhielm C. A. Cessation and onset of muscle capillary flow at simultaneously reduced perfusion and transmural pressure. Int. J. Microcirc. Clin. Exp. 6:1987;215.
36. Wang P., Ba Z. F., Stepp K. J., Chaudry I. H. Pentoxifylline attenuates the depressed endothelial cell function and vascular muscle contractility following trauma and hemorrhagic shock. J. Trauma. 39:1995;121.
37. Bessler H., Gilgal R., Djaldetti M., Zahavi I. Effect of pentoxifylline on the phagocytic activity, cAMP levels, and superoxide anion production by monocytes and polymorphonuclear cells. J. Leukoc. Biol. 40:1986;747.
38. Yonemaru M., Hatherill J. R., Hoffmann H., Zheng H., Ishii K., Raffin T. A. Pentoxifylline does not attenuate acute lung injury in the absence of granulocytes. J. Appl. Physiol. 71:1991;342.
39. Harvath L., Robbins J. D., Russell A. A., Seamon K. B. cAMP and human neutrophil chemotaxis. J. Immunol. 146:1991;224.
40. Wright C. D., Kuipers P. J., Kobylarz-Singer D., Davall L. J., Klinkefus B. A., Weishaar R. D. Differential inhibition of human neutrophil functions. Biochem. Pharmacol. 40:1990;699.
41. Suttorp N., Weber U., Welsch T., Schudt C. Role of phosphodiesterases in the regulation of endothelial permeabilityin vitro. J. Clin. Invest. 91:1993;1421.